RankAlpha logo
Back to Rankings

GOVX

GeoVax LabsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The post-earnings update sharpened the core bull case: GEO-MVA is positioned as the lead asset, management says Phase 3 can proceed in 2H 2026 after EMA alignment, and manufacturing readiness has been completed [#PR-2026-04-15]. At an approximately $8.2 million market cap, even partial de-risking of that pathway could matter disproportionately.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Execution and timing risk around starting the planned GEO-MVA Phase 3 study in the second half of 2026 [#PR-2026-04-15].
Momentum
79
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.05 · Bull $1.90 · Bear $0.40
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $250.00
Why
Momentum79 · Δ7d -
Value41 · Δ7d +0.1
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
79
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-17.6
Sentiment
0
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade D. Momentum 78.7 / Value 41.1 / Sentiment 0.0

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$7.29M
Beta
3.77
Shares Out
43.3M
P/E (TTM) · Derived
-0.0
P/S (TTM)
2.45
P/FCF (TTM) · Derived
-0.10
Rev YoY
-100.0%
EPS YoY
+65.7%
Gross Margin
-
Op Margin
-761.6%
Net Debt
-$5.51M
Current Ratio
3.57
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology